The 130-year old healthcare conglomerate sells everything from baby shampoo to surgical staples and cancer drugs (it also divested itself of Splenda, the artificial sweetener.) That diversification helped buoy giant J&J in 2015; the company’s strong pharmaceutical sales made up for the less impressive performances of its consumer and medical device divisions. The company’s revenues grew 2.6% in the US, but slid 5.7% worldwide in 2015, largely due to currency fluctuations and the sharp decline in sales of its Hepatitis C drug, Olysio.
News about Johnson & Johnson
There's a lot of nuance involved here.
If you want to invest like Donald Trump.
Democrats and Republicans are both promising fresh action on drug prices.
Here's a list of the Republican presidential candidate's wealthiest proponents.
Videos about Johnson & Johnson
Hate New Year's resolutions? These Most Powerful Women tell their tips and tricks to ring in the New Year the right way.